New combo aims to outsmart resistant lung cancer

NCT ID NCT04467723

Recruiting now Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding pirfenidone to the immunotherapy drug atezolizumab can help shrink tumors and prevent treatment resistance in people with advanced or returning non-small cell lung cancer. About 25 adults with stage IV or recurrent NSCLC who have already tried at least one prior treatment will receive the combination. The main goals are to check safety and see how well the drugs control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC STAGE IV NSCLC, RECURRENT

Contacts and locations

Locations

The University of Kansas Cancer Center (KUCC)
NOT_YET_RECRUITING

Fairway, Kansas, 66205, United States
The University of Kansas Cancer Center, Westwood Campus
RECRUITING

Kansas City, Kansas, 66205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.